NCPC New Drug Research & Development

NCPC New Drug Research & Development is the primary innovation hub for the North China Pharmaceutical Group Corporation (NCPC), one of China's largest pharmaceutical enterprises. The company focuses on the research and development of novel small molecules and biologics, particularly in the fields of oncology, infectious diseases, and autoimmune disorders. It operates several state-level laboratories and platforms dedicated to microbial medicine and antibody engineering. Notable achievements include the development of ormuzumab, a first-in-class human monoclonal antibody for rabies post-exposure prophylaxis. The center plays a critical role in NCPC's strategic shift from traditional antibiotic production to the development of high-tech biopharmaceuticals. Its capabilities span the entire drug development lifecycle, from lead optimization to clinical trial management.